Anixa Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Anixa Biosciences, Inc. carries a market capitalization of 84.49M, placing it among publicly traded companies globally. Its enterprise value stands at 83.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 84.49M |
| Enterprise Value | 83.98M |
Share Statistics
Anixa Biosciences, Inc. currently has 33.46M shares outstanding.
| Shares Outstanding | 33.46M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.39 |
| P/TBV Ratio | 7.17 |
| P/FCF Ratio | -14.42 |
| P/OCF Ratio | -14.42 |
Financial Position
Anixa Biosciences, Inc. maintains a current ratio of 12.18, meaning it holds 12.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.18 |
| Quick Ratio | 11.49 |
| Debt / Equity | 1.39 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -60.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Anixa Biosciences, Inc.'s stock has declined approximately -9.67742% over the past 52 weeks. The 50-day moving average sits at 2.82, while the 200-day moving average is 3.33.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.67742% |
| 50-Day Moving Average | 2.82 |
| 200-Day Moving Average | 3.33 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -10.99M, while operating income came in at -11.03M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.03M |
| Pretax Income | -10.40M |
| Net Income | -10.31M |
| EBITDA | -10.99M |
| EBIT | -11.03M |
| Earnings Per Share (EPS) | -0.32 |
Balance Sheet
Anixa Biosciences, Inc. holds 14.20M in cash and equivalents against 193,000.00 in total debt, resulting in a net debt position of -1.55M. Total book value stands at -253.91M, with working capital of 13.81M providing operational flexibility.
| Cash & Cash Equivalents | 14.20M |
| Total Debt | 193,000.00 |
| Net Debt | -1.55M |
| Equity (Book Value) | -253.91M |
| Book Value Per Share | -7.78 |
| Working Capital | 13.81M |
Cash Flow
Anixa Biosciences, Inc. produced -6.88M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.88M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.88M |
| FCF Per Share | -0.21 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -4.01 |
| FCF Yield | -6.93 |
Stock Splits
Anixa Biosciences, Inc.'s most recent stock split took place on June 26, 2015 with a 25:1 split ratio.
| Last Split Date | 6/26/2015 |
| Split Ratio | 25:1 |
Scores
Anixa Biosciences, Inc. posts an Altman Z-Score of 18.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 18.26 |